Factors Associated With Mortality in US Adults With NAFLD

November 8-12, 2019; Boston, Massachusetts
Presence of advanced hepatic fibrosis, CKD, and elevated cardiac risk score increase risk of mortality in all patients with NAFLD, regardless of BMI.
Format: Microsoft PowerPoint (.ppt)
File Size: 277 KB
Released: November 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Expert insight on the burden and impact of HBV infection, as well as strategies to overcome barriers to vaccination, from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2022 Expired: March 21, 2023

Free slides from CCO featuring data on the prevalence, assessment, and treatment landscape for NASH in people living with HIV.

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Released: February 9, 2022

Expert commentary by Dr Mark S. Sulkowski on the importance of investigating elevated liver enzymes in patients with HIV, from Clinical Care Options (CCO)

Mark S. Sulkowski, MD Released: January 10, 2022

Expert insights on emerging NAFLD/NASH treatments from Dr. Stephen Harrison and Clinical Care Options (CCO)

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings